{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:24:40Z","timestamp":1789428280289,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005683","name":"Kyoto University","doi-asserted-by":"publisher","award":["G0697"],"award-info":[{"award-number":["G0697"]}],"id":[{"id":"10.13039\/501100005683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19198"],"award-info":[{"award-number":["24K19198"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcyt.2026.102065","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:36:36Z","timestamp":1768710996000},"page":"102065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-0248","authenticated-orcid":false,"given":"Yusuke","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-0421","authenticated-orcid":false,"given":"Tomoyasu","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3442","authenticated-orcid":false,"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6508-9432","authenticated-orcid":false,"given":"Noriyoshi","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8868-1661","authenticated-orcid":false,"given":"Takashi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7469-1276","authenticated-orcid":false,"given":"Kotaro","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-6145","authenticated-orcid":false,"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-4284","authenticated-orcid":false,"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jcyt.2026.102065_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jcyt.2026.102065_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.jcyt.2026.102065_bib0004","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jcyt.2026.102065_bib0005","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102065_bib0006","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102065_bib0007","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102065_bib0008","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12185-024-03879-w","article-title":"Current treatment approach and future perspectives in B cell lymphoma","volume":"121","author":"Yamauchi","year":"2025","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102065_bib0009","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.jcyt.2026.102065_bib0011","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102065_bib0012","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jha2.1043","article-title":"Fluctuation of physical function during chimeric antigen receptor T-cell therapy during rehabilitation intervention: real-world data and risk factor analyses","volume":"5","author":"Hamada","year":"2024","journal-title":"EJHaem"},{"issue":"16","key":"10.1016\/j.jcyt.2026.102065_bib0013","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","article-title":"Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma","volume":"17","author":"Sesques","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102065_bib0015","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/bloodadvances.2023011896","article-title":"Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma","volume":"8","author":"Nie","year":"2024","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jcyt.2026.102065_bib0016","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3390\/cancers17172876","article-title":"Endothelial injury following CAR-T cell immunotherapy for hematological malignancies","volume":"17","author":"Demosthenous","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-022-00777-4","article-title":"Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma","volume":"13","author":"Acosta-Medina","year":"2023","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.jcyt.2026.102065_bib0018","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102065_bib0019","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102065_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102065_bib0022","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102065_bib0023","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtct.2024.01.073","article-title":"Clinical impact of cytokine release syndrome on prolonged hematotoxicity after chimeric antigen receptor T cell therapy: KyoTox A-score, a novel prediction model","volume":"30","author":"Nakamura","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102065_bib0024","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102065_bib0025","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0026","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102065_bib0027","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102065_bib0028","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102065_bib0029","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102065_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215920","article-title":"Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective","volume":"550","author":"Si","year":"2022","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102065_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.12.020","article-title":"Apoptosis of hematopoietic stem cells contributes to bone marrow suppression following chimeric antigen receptor T cell therapy","volume":"29","author":"Read","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102065_bib0032","article-title":"Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy","author":"Tashiro","year":"2025","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0033","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10238-024-01373-5","article-title":"Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy","volume":"24","author":"Nakamura","year":"2024","journal-title":"Clin Exp Med"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0034","first-page":"24","article-title":"Assessment of hematologic progenitor engraftment by complete reticulocyte maturation parameters after autologous and allogeneic hematopoietic stem cell transplantation","volume":"86","author":"Torres","year":"2001","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.transproceed.2010.12.030","article-title":"Predictive value of immature reticulocyte and platelet fractions in hematopoietic recovery of allograft patients","volume":"43","author":"Gon\u00e7alo","year":"2011","journal-title":"Transplant Proc"},{"issue":"21","key":"10.1016\/j.jcyt.2026.102065_bib0036","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102065_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1144414","article-title":"CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern?","volume":"14","author":"Velasco","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"issue":"66","key":"10.1016\/j.jcyt.2026.102065_bib0039","doi-asserted-by":"crossref","first-page":"110118","DOI":"10.18632\/oncotarget.22654","article-title":"Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding","volume":"8","author":"Waldera-Lupa","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102065_bib0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.56875\/2589-0646.1024","article-title":"Chimeric antigen receptor T-cell therapies in lymphoma patients with central nervous system involvement","volume":"15","author":"Yi","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"Supplement_1","key":"10.1016\/j.jcyt.2026.102065_bib0041","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium","volume":"134","author":"Nora Bennani","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102065_bib0042","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102065_bib0043","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102065_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2024.100025","article-title":"EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy","volume":"1","author":"Gavriilaki","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41408-023-00895-7","article-title":"Metabolic PET\/CT analysis of aggressive non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity","volume":"13","author":"Breen","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102065_bib0046","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102065_bib0047","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-024-01022-w","article-title":"Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma","volume":"14","author":"Keijzer","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102065_bib0048","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.21037\/qims-24-1737","article-title":"18F-fluorodeoxyglucose positron emission tomography-compute tomography parameters for predicting the prognosis and toxicity in children and young adults with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"15","author":"Yao","year":"2025","journal-title":"Quant Imaging Med Surg"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102065_bib0049","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtct.2025.03.011","article-title":"Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma","volume":"31","author":"Shouval","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"10.1016\/j.jcyt.2026.102065_bib0050","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1182\/bloodadvances.2023011027","article-title":"ICANS prophylaxis: potentially transformative but elusive","volume":"7","author":"Dowling","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102065_bib0051","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102065_bib0052","first-page":"531","article-title":"Impact of neurotoxicity and steroid therapy on cancer progression-free survival in lymphoma patients treated with anti-CD19 CAR T cells","volume":"12","author":"Pensato","year":"2024","journal-title":"Neurooncol Pract"},{"issue":"20","key":"10.1016\/j.jcyt.2026.102065_bib0053","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:18:15Z","timestamp":1782199095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1465324926000216"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102065","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102065"}}